血清嗜酸性粒细胞阳离子蛋白水平与药物洗脱支架晚期支架内再狭窄的相关性

目的：分析嗜酸性粒细胞阳离子蛋白（Eosinophil cationic protein, ECP）与药物洗脱支架（DES）晚期支架内再狭窄的相关性; 方法：入组202位我院植入药物洗脱支架并在超过1年后返院复查造影患者,根据复查造影结果分为支架内再狭窄组及无支架内再狭窄组,应用夹心酶联免疫吸附（ELISA）法测定血清嗜酸性粒细胞阳离子蛋白水平并比较其在两组间差异。在亚组分析中,进一步根据支架载药涂层将患者分为永久涂层-DES组（DP-DES组）及可降解涂层-DES组（BP-DES组）。 结果：支架内再狭窄组血清ECP水平明显高于无支架内再狭窄组[20.6 (6.7, 45.6) vs. 10.5 (3.6, 25.3) μg/mL; p=0.003],多因素回归显示ECP水平(p=0.037)、手术年龄(p=0.029)是晚期支架内再狭窄形成的独立危险因）。亚组分析显示血清ECP水平在应用DP-DES的支架内再狭窄患者明显高于无支架内再狭窄患者[24.9 (8.4, 59.1) vs. 10.5 (3.1, 22.4) μg/mL, p= 0.002],应用BP-DES患者,两组之间无统计学差异。 结论：血清ECP水平在晚期支架内再狭窄患者中显著升高,同时其升高与支架载药涂层类型相关。     

冠脉支架术后患者支架内再狭窄原因的回顾性研究

目的 通过对冠脉支架植入术后复查冠脉造影患者的回顾性分析,研究引起支架内再狭窄(ISR)的可能原因.方法 入选2009年～2010年所有复查造影的冠心病支架治疗患者73例,将其分成支架内再狭窄组及无再狭窄组,分析两组间可能导致支架内再狭窄的因素间差异.结果 73例患者共植入177枚支架,其中有22枚支架发生再狭窄(支架内再狭窄定义为随访时造影提示支架内管腔内径损失≥50%).分析两组基本临床资料特征及支架长度、直径,是否为药物涂层支架等因素;支架内再狭窄组及无再狭窄组在吸烟、2型糖尿病、支架长度、直径和药物/非药物支架方面有显著差异(P ＜0.05).Cox比例风险回归模型显示仅支架长度(P=0.009)、直径(P=0.029)和药物/非药物支架(P=0.026)为冠心病介入患者发生ISR的预测因子.结论 冠脉支架植入后发生再狭窄的主要原因为支架长度、直径及是否为药物支架.     

药物涂层球囊在冠状动脉支架再狭窄介入治疗中的应用价值

目的 探讨冠状动脉支架内再狭窄患者中运用药物涂层球囊(DCB)处理的有效性及安全性.方法 对60例经冠脉造影证实冠状动脉内支架再狭窄患者,36例予以药物涂层球囊治疗,24例予以药物洗脱支架(DES)治疗,随访6个月并复查冠脉造影进行对比.结果 两组患者基线资料上差异无统计学意义(P>0.05);两组患者术后即刻药物洗脱...     

肾小球滤过率与冠状动脉支架内再狭窄的相关性分析

目的 :探索冠状动脉(冠脉)药物洗脱支架植入(以下简称支架植入)术后随访期估算肾小球滤过率(estimated glomerular filtration rate, e GFR)与支架植入术后再狭窄(in-stent restenosis, ISR)间的关系。方法:以中国冠状动脉斑块进展多因素回顾分析研究中的患者为对象,病例均于2010年1月至2016年7月间在各中心进行冠脉造影检查,并在之后12～24个月(平均为13个月)内进行冠脉造影复查,采用二元Logistics回归分析评估随访期eGFR与ISR间的关系,初步探索导致ISR发生的危险因素。结果 :本研究共纳入符合标准的冠心病患者1 790例,随访期全体患者eGFR平均值为89.97 mL/(min·1.73m~2),按照随访期复查冠脉造影有无ISR,分为ISR组(n=200)和无ISR组(n=1590)。其中,ISR组患者在随访期间的eGFR低于无ISR组[(86.50±25.69) m L/(min·1.73 m~2)比(90.64±26.59)mL/(min·1.73 m~2),P=0.038]。二元Logistics回归分析提示,导致ISR的危险因素包括植入支架的个数(OR=1.478,95%CI 1.177～1.855, P=0.001)、基线期C反应蛋白升高(OR=1.006, 95%CI 1.002～1.011, P=0.007),而随访期间相对较高的eGFR是ISR的保护性因素(OR=0.990,95%CI 0.982～0.999, P=0.022)。结论:在eGFR基本正常的冠心病患者中,较低的随访期e GFR水平与其接受冠脉药物洗脱支架植入术后的ISR发生率密切相关。     

紫杉醇药物涂层球囊治疗冠状动脉支架内再狭窄的效果及近期预后观察

目的 探讨紫杉醇药物涂层球囊(DCB)治疗冠状动脉支架内再狭窄(ISR)的效果及近期预后.方法 选取2016年5月—2019年6月收治的冠心病行经皮冠状动脉介入(PCI)术后ISR患者70例,根据治疗方法的不同分为观察组36例和对照组34例,观察组采用DCB治疗,对照组采用药物涂层支架(DES)治疗.比较两组再次PCI...     

B型钠尿肽与冠状动脉支架植入术后再狭窄的关系

目的:探讨冠心病患者血浆B型钠尿肽(BNP)水平与冠状动脉支架内再狭窄(ISR)的关系.方法:选择114例接受冠状动脉支架植入术(PCI)以及术后1年内再次接受冠状动脉造影检查的患者,分为ISR组和非ISR组,分别在PCI术前、出院前和复查冠状动脉造影前测定血浆BNP水平,两组患者分别比较相应时间点的BNP水平.结果:ISR组和非ISR组PCI术前、出院前及复查冠状动脉造影前的BNP水平,差异有统计学意义[分别为(278±12.3)pg/mL vs(33.9±13.0)pg/mL,(235±22.7)pg/mL vs(30.1±16.6)pg/mL,(299±26.1)pg/mL vs(27.8±10.5)pg/mL,P<0.05].多因素回归分析显示,血浆BN P水平与ISR显著相关(DR=1.780,95%CI为1.002～3.090).结论:血浆BNP可作为ISR的有用预测指标.     

核苷酸结合寡聚化结构域样受体蛋白3炎症小体对冠状动脉支架植入术后支架内再狭窄的影响

目的 探讨核苷酸结合寡聚化结构域样受体蛋白3(NLRP3)炎症小体的表达水平与冠状动脉支架植入术后支架内再狭窄(ISR)的相关关系.方法 选取住院治疗并成功行初次经皮冠状动脉介入治疗(PCI)术的患者150例,术前、术后24 h应用免疫印迹法定量分析NLRP3.1年后复查冠状动脉造影,根据ISR诊断标准将患者分为ISR组(n=22)与对照组(n =128),分析NLRP3表达水平与ISR严重程度的相关关系.结果 1年后复查时,ISR组NLRP3表达水平较对照组升高,差异有统计学意义(P＜0.05),且在一定范围内随着ISR严重程度的升高,NLRP3表达水平可逐渐增高,二者存在简单线性正相关关系(r =0.862,P=0.001).结论 NLRP3表达水平与冠状动脉ISR严重程度呈正相关.     

药物洗脱支架治疗无保护左主干病变的疗效及安全性分析

目的 探讨药物洗脱支架(DES)植入在高危无保护左主干(ULMCA)患者的安全性及近、中期疗效.方法 入选42例ULMCA病变患者,分为DES组和裸金属支架(BMS)组,入选标准为:ST段抬高心肌梗死,非ST段抬高心肌梗死,心源性休克,或Euro SCORE积分≥6分.22例植入了DES,20例植入了BMS,并进行随访,观察药物支架安全性.结果 随访至1年,BMS组1例晚期血栓形成,3例支架内再狭窄,再次进行血运重建,DES组无一例血运重建(20.O%孵.0,P=0.048).两组主要不良心脏事件(65.0%υs19.O%,P=O.004)存在统计学差异.结论 DES在ULMCA中安全可靠,在缺血改善的同时并没有增加早期及晚期支架内血栓形成的风险.     

经皮冠状动脉介入治疗术前白蛋白水平与冠状动脉病变程度及支架内再狭窄的关系

目的探讨经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术前白蛋白水平与冠状动脉病变程度及支架内再狭窄(in-stent restenosis,ISR)的关系。方法成功行PCI术的冠心病患者263例,依据术后12个月冠状动脉造影结果分为2组,110例合并ISR者为ISR组,153例无ISR者为对照组。比较2组临床资料及生化指标的差异。结果 ISR组合并糖尿病比例(34.5%)高于对照组(19.7%)(P0.05),血清白蛋白水平[(36.96±4.38)g/L]低于对照组[(39.39±4.26)g/L](P0.05);白蛋白水平与冠状动脉病变Gensini积分呈负相关(r=-1.080,P=0.011);logistic回归分析示糖尿病病史为ISR的危险因素(OR=2.044,95%CI:1.143~3.657,P=0.016),较高水平的白蛋白是保护因素(OR=0.876,95%CI:0.821~0.934,P=0.011)。结论冠心病患者术前白蛋白水平越低,冠状动脉病变程度越重,低水平白蛋白可能是ISR的危险因素。     

红细胞分布宽度与冠心病患者经皮冠状动脉介入治疗术后支架内再狭窄的相关性研究

目的 探讨红细胞分布宽度(RDW)与冠心病患者经皮冠状动脉介入治疗(PCI)术后支架内再狭窄(ISR)的相关性.方法 选取2015年3月至2016年3月在我科行冠状动脉造影确诊为冠心病并行药物洗脱支架(DES)置入术的患者978例,其中493例患者(50.41%)在术后6~12个月在我院复查了冠状动脉造影.根据复查造影结果分为再狭窄组和非再狭窄组.收集患者的基础资料、各项实验室指标及冠状动脉介入术手术记录,分析两组间可能导致支架内再狭窄的因素.结果 再狭窄组51例(10.34%),非再狭窄组442例(89.66%).两组患者基线特征相似,在性别、年龄、体质量指数、合并高血压、冠心病家族史、术后长期服用他汀类药物情况及随访间期方面差异均无统计学意义(P均>0.05).再狭窄组合并糖尿病患者比例高于非再狭窄组(37.3%比22.6%,P=0.021));再狭窄组患者吸烟率更高(52.9%比35.7%,P=0.016).实验室检查方面,两组患者血脂水平及全血细胞分析中的白细胞、红细胞、血红蛋白、血小板计数差异均无统计学意义(P均>0.05).再狭窄组患者血清RDW[13.4(13.00, 13.80)比12.7(12.40,13.10),P<0.01]及hs-CRP[3.15(2.32,4.63)比1.33(0.63,3.16),P<0.01]水平显著升高.再狭窄组患者置入的支架更长[(21.87±5.20)mm比(19.14±4.87)mm,P<0.01)],支架直径更小[(2.87 ± 0.38)mm 比(3.09 ± 0.36)mm,P<0.01)],串联支架例数更多(45.1%比30.8%,P=0.038).多因素 Logistic 回归分析结果显示,校正年龄、性别后,RDW(OR=2.396,95%CI:1.655~3.471;P<0.01),hs-CRP(OR=1.052,95%CI:1.001~1.105;P=0.044),糖尿病(OR=2.029,95%CI:1.004~4.100;P=0.049),吸烟(OR=2.252,95%CI:1.060~4.783;P=0.035),支架长度(OR=1.149, 95%CI:1.072-1.230;P<0.01),支架直径(OR=0.210,95%CI:0.079~0.558;P=0.002)和串联支架(OR=2.306,95%CI:1.162~4.575;P=0.017)是支架内再狭窄发生的独立危险因素.结论 红细胞分布宽度为冠心病患者PCI术后支架内再狭窄的独立预测因子,而慢性炎症及氧化应激反应可能为RDW升高导致ISR发生的最主要机制.     

冠状动脉CTA斑块特征评价支架内再狭窄风险

目的 探讨冠状动脉CTA斑块特征评估植入支架后发生支架内再狭窄（ISR）的风险。方法 对166例患者于支架植入前行冠状动脉CTA检查,观察血管狭窄程度和斑块特征,并于植入支架后6~18个月内复查冠状动脉造影;根据有无ISR,将其分为ISR组（n=16）与无ISR组（n=150）,比较两组间的差异;采用多因素Logistic回归分析获得ISR的危险因素,以ROC曲线评价各因素诊断ISR的效能。结果 ISR组病变长度,非钙化斑块、点状钙化、正性重构比例和正性重构指数均大于无ISR组（P均<0.05）。多因素Logistic回归分析结果显示,非钙化斑块[回归系数（B）=1.89,优势比（OR）=6.63,P=0.01]、点状钙化（B=1.28,OR=3.59,P=0.01）、正性重构（B=2.17,OR=8.71,P<0.01）、病变长度（B=0.05,OR=1.05,P=0.04）是导致ISR的危险因素。病变长度及正性重构指数诊断ISR的ROC曲线下面积（AUC）分别为0.70和0.82（P均<0.01）,联合上述斑块特征预判ISR的AUC为0.87（P<0.01）。结论 病变长度、正性重构、非钙化斑块、点状钙化可用于评估冠状动脉支架植入后发生ISR的风险。     

Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents

Background : We tested the hypothesis that plasma levels of plasminogen activator inhibitor-1 (PAI-1) are influenced by percutaneous coronary intervention (PCI) with the implantation of drug eluting stents (DES) and are able to predict the occurrence of in-stent restenosis (ISR). Methods and results : PAI-1 active antigen plasma levels were determined in 75 patients before and 24 h after PCI with DES implantation. Patients with ISR after six to eight months (16%) showed significantly lower PAI-1 plasma levels before PCI (ISR, 11.7 ± 8.1 ng mL⁻¹; non-ISR, 22.8 ± 18.8 ng mL⁻¹; P  < 0.05). PAI-1 levels in the lowest tertile were associated with a 9.5-fold increased risk of ISR, independent of clinical risk factors, angiographic or procedural characteristics, compared to the highest tertile ( P  <   0.05). The induced change of PAI-1 active antigen 24 h after PCI was significantly higher in patients with ISR (ISR, +5.6 ± 8.0 ng mL⁻¹; non-ISR, −3.2 ± 12.1 ng mL⁻¹; P  <   0.05) with positive correlation to late lumen loss ( r  =   0.30; P  <   0.05). Conclusions : ISR after DES implantation is significantly related to plasma levels of PAI-1 active antigen before and after PCI. If confirmed by larger multicenter studies, the determination of PAI-1 plasma levels might be clinically helpful in the identification of patients at high risk of developing of ISR, even after DES implantation.     

Relationship between hyporesponsiveness to clopidogrel measured by thrombelastography and in stent restenosis in patients undergoing percutaneous coronary intervention

ObjectivesThe relationship between hyporesponsiveness to clopidogrel and in stent restenosis (ISR) was analyzed, and the cut-off value of hyporesponsiveness to clopidogrel for ISR was evaluated.Design and methods861 consecutive patients enrolled and patients' inhibition rates in arachidonic acid (AA) and adenosine 5′-diphosphate (ADP) pathways were measured by thrombelastography (TEG) system. Patients were divided into ISR and non-ISR groups according to the results of coronary angiography. Correlation between hyporesponsiveness to clopidogrel and ISR was analyzed.Results249 patients were in ISR group and 612 patients were in non-ISR group. The frequency of clopidogrel hyporesponsiveness in ISR group was significantly higher than that in non-ISR group (P < 0.01). Inhibition rates in AA and ADP pathways in ISR group were lower than those in non-ISR group (P < 0.01). The inhibition rate in ADP pathway was inversely correlated with (r = − 0.225, P = 0.001) the severity of ISR. After being adjusted for traditional covariates, the inhibition rate in ADP pathway (β = − 0.191, R² = 0.011, P = 0.013) remained independently associated with the severity of ISR; clopidogrel hyporesponsiveness was an independent risk factor of ISR (HR 6.62, 95% CI 2.84–15.49, P = 0.001). ROC curve analysis showed that the predictive cut-off value of the inhibition rate in ADP pathway for ISR was 10.1%.ConclusionsThe inhibition rate in ADP pathway is inversely related to the ISR severity. Clopidogrel hyporesponsiveness is an independent risk factor for ISR and can predict the risk of ISR.     

Revisiting the role of durable polymers in cardiovascular devices

Introduction: Polymers are an essential component of drug-eluting stents (DES) used to control drug release but remain the most controversial component of DES technology. There are two types of polymers employed in DES: durable polymer based DES (DP-DES) and biodegradable polymer DES (BP-DES). First-generation DES were exclusively composed of DP and demonstrated increased rates of late stent failure due in part to poor polymer biocompatibility. Newer generations DES use more biocompatible durable polymers or biodegradable polymers.

Areas covered: We will cover issues identified with 1st-generation DP-DES, areas of success and failure in 2nd-generation DP-DES and examine the promise and shortcomings of BP-DES. Briefly, fluorinated polymers used in 2nd-generation DP-DES have excellent anti-thrombogenicity and better biocompatibility than 1st-generation DES polymers. However, these devices lead to persistent drug exposure to the endothelium which impairs endothelial function and predisposes towards neoatherosclerosis. Meanwhile, BP-DES has shortened the duration of drug exposure which might be beneficial for endothelial functional recovery leading to less neoatherosclerosis. However, it remains uncertain whether the long-term biocompatibility of bare metal surfaces is better than that of polymer-coated metals.

Expert commentary: Each technology has distinct advantages, which can be optimized depending upon the particular characteristics of the patient being treated.     

冠心病PCI术后再狭窄患者IL-18基因多态性的研究

目的研究白细胞介素-18（IL-18）基因多态性对冠心病患者经皮冠状动脉介入术（PCI）术后支架内再狭窄（ISR）易感性的潜在影响。方法将PCI术后的241例有再发缺血临床症状的冠心病患者作为研究对象,并根据冠状动脉造影结果分为支架内再狭窄（ISR）组（ISR组,n=68）和非ISR组（n=173）,另选择109例排除冠心病的人群作为对照组。采用聚合酶链反应对IL-18基因型进行检测,同时测定血清IL-18浓度。结果 ISR组、非ISR组患者G等位基因频率分别为0.93、0.83,二者明显高于对照组（0.73,P〈0.01）,ISR组患者的G等位基因频率明显高非ISR组（P〈0.01）。ISR组、非ISR组患者GG基因型频率分别为0.87、0.69,二者明显高于对照组（0.54,P〈0.01）,ISR组患者GG基因型频率明显高非ISR组（P〈0.01）。ISR组、非ISR组患者血清IL-18浓度分别为（309.39±86.75）、（245.37±59.04）ng/L,明显高于对照组[（138.41±47.28）ng/L]（P〈0.01）,ISR组患者血清IL-18浓度明显高于非ISR组（P〈0.01）。结论 IL-18启动子-137G/C基因多态性可能会影响血清IL-18浓度及PCI术后再狭窄发生的易感性。     

术前血清胆红素预测冠心病支架再狭窄价值

目的 探讨术前血清胆红素的水平与冠心病支架术后再狭窄的相关性.方法 纳入2013-2014年入住浙江大学医学院附属第二医院行冠脉造影接受支架植入治疗,并于术后6月到12月之间再次入院行冠脉造影复查的249例冠心病患者,根据支架内有无再狭窄分为支架内再狭窄组和无再狭窄组,通过比较两组患者术前血清胆红素的水平,分析其与冠心病支架内再狭窄的关系.结果 血清总胆红素(TBIL)冠心病支架内再狭窄组(9.93±3.871μmol/L)水平低于无再狭窄组(12.08±4.67) μmol/L,(P=0.000),血清直接胆红素(DBIL)冠心病支架内再狭窄组(3.17±1.60) μmoL/L水平低于无再狭窄组(3.89±1.83)μmol/L,(P =0.002),血清间接胆红素(IBIL)冠心病支架内再狭窄组(6.76±2.82)μmol/L水平低于无再狭窄组(8.17±3.39)μmol/L,(P =0.001);差异具有统计学意义(P＜0.05).Spearman相关回归分析,结果显示,TBIL、DBIL、IBIL与再狭窄呈负相关,(P＜0.05),血清胆红素越低,再狭窄发生率越高.结论 冠心病再狭窄患者血清TBIL、DBIL、IBIL偏低,再狭窄与血清TBIL、DBIL、IBIL相关性高.术前TBIL、DBIL、IBIL可作为冠心病支架内再狭窄的预测因素.     

药物涂层球囊治疗冠状动脉原位病变的有效性及安全性

目的 观察药物涂层球囊介入治疗对冠状动脉原位病变患者术后MACE事件发生的影响。方法 选择于2021年2月至2022年6月就诊且需进行介入治疗的冠状动脉原位病变的85例患者,用随机数字表法分为观察组和对照组。其中40例观察组患者接受药物涂层球囊介入治疗,45例对照组患者接受药物洗脱支架介入治疗。分别在术前及术后不同时间检测管腔直径。比较两组手术即刻成功率、术中并发症发生情况;比较两组患者术前、术后即刻、术后6个月最小管腔直径（MLD）和管腔狭窄程度;评估两组术后6个月时晚期管腔丢失（LLL）;观察两组术后6个月内不良心血管事件（MACE）和靶血管病变处再狭窄情况。结果 观察组即刻手术成功率为95.00%,对照组即刻手术成功率为97.78%,两组即刻手术成功率差异无统计学意义（P>0.05）;两组患者术中并发症发生差异无统计学意义（P>0.05）;观察组MLD术后即刻与术后6个月均低于对照组（P<0.05）;观察组管腔狭窄程度术后即刻均高于对照组（P<0.05）,而术后6个月与对照组比较差异无统计学意义（P>0.05）;观察组管腔再狭窄小于对照组,累计MACE发生率低于对照组（P<0.05）。结论 药物涂层球囊介入治疗即刻成功率较高,明显改善动脉血管狭窄情况,安全性较好。     

Long-term safety of drug-eluting stents in patients on warfarin treatment

Abstract

Background. The safety of drug-eluting stents (DES) in patients on long-term warfarin treatment has been questioned due to high risk of bleeding complications during prolonged triple (aspirin, clopidogrel, and warfarin) antithrombotic therapy. Methods. We analysed the long-term outcome of 415 consecutive warfarin-treated patients who underwent DES (n = 191) or bare-metal (n = 224) stenting in six hospitals. Results. The mean duration of triple therapy was longer (4.2 ± 3.1 versus 2.1 ± 1.8 months; P < 0.001) in the DES group. The incidence of major adverse cardiovascular and cerebrovascular events was comparable in the DES and bare-metal groups (39.8% versus 42.4%; P = 0.59) during a median follow-up of 3.5 years. Similarly, major bleeding events occurred equally often in both study groups (14.7% versus 12.9%). Six patients in the DES group and seven patients in the bare-metal group suffered stent thrombosis (3.1% versus 3.1%). In the propensity score analyses of 101 matched pairs, the outcome was similar in the two groups. Conclusion. Selective use of DES with a short triple therapy seems to be safe in patients with warfarin therapy. The prognosis of this fragile patient population is quite poor, and major bleeding events are common irrespective of stent type.     

血浆致动脉硬化指数对颈动脉支架内再狭窄的预测价值

目的 探讨血浆致动脉硬化指数(AIP)对颈动脉支架内再狭窄(ISR)的预测价值.方法 回顾性纳入2017年3月至2019年12月在四川省人民医院接受颈动脉支架置入术(CAS)患者.根据颈动脉数字减影血管造影(DSA)结果将患者分为再狭窄组和非再狭窄组,比较两组间AIP及血脂水平差异.分析颈动脉ISR的独立危险因素及AI...     

CysC、Hcy、MPV、NT-proBNP对STEMI术后再狭窄的影响

目的分析急性ST段抬高型心肌梗死患者经冠状动脉支架术(PCI)治疗后再狭窄的相关危险因素。方法选取2015年2月至2019年2月在本院心内科进行支架植入手术,且在术后6~12个月内完成冠状动脉造影复查的137例患者。根据造影复查结果将其分为支架内再狭窄(ISR)组和非ISR组。其中ISR组34例,非ISR组103例。对两组患者的病史资料,心脏超声情况,血液生化指标,植入支架情况,术后服药情况,主要心脏不良事件等进行回顾性分析,使用多因素Logistic回归分析其与PCI术后ISR的相关性。结果所有患者ISR发生率为24.8%。单因素分析发现,与非ISR组比较,ISR组在吸烟史、高血压、糖尿病病史、冠心病家族史、MPV、CysC、Hcy、NT-proBNP、LDL-C、ApoB、NLR、支架植入直径(≥3mm)、存在残余狭窄、术后未规律双抗及他汀类药物方面差异具有显著性统计学意义;多因素Logistic回归分析显示,糖尿病(OR=2.205,95%CI:1.069~4.531,P=0.031)、MPV(OR=1.873,95CI:1.141~4.275,P=0.016)、CysC(OR=1.356,95%CI:1.244~2.803,P=0.028)、Hcy(OR=1.824,95%CI:0.709~4.706,P=0.012)、NT-proBNP(OR=1.106,95%CI:1.003~1.264,P=0.033)、NLR(OR=1.765,95%CI:0.439~1.275,P=0.038)是ISR的危险因素。结论糖尿病、MPV、CysC、Hcy、BNP、NLR是PCI术后ISR的危险因素。